Evidence map›Paper›PMID 29103974›Full record

ArticleBioorganic & medicinal chemistry letters2017

Optimization of a series of heterocycles as survival motor neuron gene transcription enhancers.

Sungwoon Choi, Alyssa N Calder, Eliza H Miller, Kierstyn P Anderson, Dawid K Fiejtek, Anne Rietz, Hongxia Li, Jonathan J Cherry, Kevin M Quist, Xuechao Xing and 5 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioorganic & medicinal chemistry letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Sungwoon ChoiLaboratory for Drug Discovery in Neurodegeneration, Brigham and Women's Hospital and Harvard Medical School, 65 Landsdowne Street, Cambridge, MA, USA.
Alyssa N CalderLaboratory for Drug Discovery in Neurodegeneration, Brigham and Women's Hospital and Harvard Medical School, 65 Landsdowne Street, Cambridge, MA, USA.
Eliza H MillerLaboratory for Drug Discovery in Neurodegeneration, Brigham and Women's Hospital and Harvard Medical School, 65 Landsdowne Street, Cambridge, MA, USA.
Kierstyn P AndersonLaboratory for Drug Discovery in Neurodegeneration, Brigham and Women's Hospital and Harvard Medical School, 65 Landsdowne Street, Cambridge, MA, USA.
Dawid K FiejtekLaboratory for Drug Discovery in Neurodegeneration, Brigham and Women's Hospital and Harvard Medical School, 65 Landsdowne Street, Cambridge, MA, USA.
Anne RietzDepartment of Dermatology, Indiana University School of Medicine, Indianapolis, IN, USA.
Hongxia LiDepartment of Dermatology, Indiana University School of Medicine, Indianapolis, IN, USA.
Jonathan J CherryDepartment of Dermatology, Indiana University School of Medicine, Indianapolis, IN, USA.
Kevin M QuistDepartment of Dermatology, Indiana University School of Medicine, Indianapolis, IN, USA.
Xuechao XingLaboratory for Drug Discovery in Neurodegeneration, Brigham and Women's Hospital and Harvard Medical School, 65 Landsdowne Street, Cambridge, MA, USA.
Marcie A GlicksmanLaboratory for Drug Discovery in Neurodegeneration, Brigham and Women's Hospital and Harvard Medical School, 65 Landsdowne Street, Cambridge, MA, USA.
Gregory D CunyLaboratory for Drug Discovery in Neurodegeneration, Brigham and Women's Hospital and Harvard Medical School, 65 Landsdowne Street, Cambridge, MA, USA.
Christian L LorsonDepartment of Veterinary Pathobiology, Bond Life Sciences Center, University of Missouri, Columbia, MO, USA.
Elliot A AndrophyDepartment of Dermatology, Indiana University School of Medicine, Indianapolis, IN, USA.
Kevin J HodgettsLaboratory for Drug Discovery in Neurodegeneration, Brigham and Women's Hospital and Harvard Medical School, 65 Landsdowne Street, Cambridge, MA, USA. Electronic address: khodgetts@bwh.harvard.edu.
Harvard University · USBrigham and Women's Hospital · USIndiana University School of MedicineIndiana University – Purdue University Indianapolis · USUniversity of Missouri · US

Funding

Cooperative lead development program for treatment of spinal muscular atrophyR01HD064850 · NICHD · INDIANA UNIVERSITY INDIANAPOLIS · PI ANDROPHY, ELLIOT J. · 2010 to 2012
$1.9M
Optimization of Compounds that Stabilize the SMN Protein for Treatment of SMAR33NS095139 · NINDS · INDIANA UNIVERSITY INDIANAPOLIS · PI ANDROPHY, ELLIOT J., HODGETTS, KEVIN · 2018 to 2019
$718k
Testing Compounds that Increase SMN levels for Efficacy in Mouse Models of SMAR21NS064349 · NINDS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI ANDROPHY, ELLIOT J. · 2009 to 2010
$484k
Optimization of drug-like compounds for treatment of spinal muscular atrophyR21HD057402 · NICHD · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI ANDROPHY, ELLIOT J. · 2008 to 2009
$478k
NICHD NIH HHS R01 HD064850NICHD NIH HHS R21 HD057402NINDS NIH HHS R21 NS064349NINDS NIH HHS R33 NS095139
6 · The paper itself

Abstract

Spinal muscular atrophy (SMA) is a neurodegenerative disorder that results from mutations in the SMN1 gene, leading to survival motor neuron (SMN) protein deficiency. One therapeutic strategy for SMA is to identify compounds that enhance the expression of the SMN2 gene, which normally only is a minor contributor to functional SMN protein production, but which is unaffected in SMA. A recent high-throughput screening campaign identified a 3,4-dihydro-4-phenyl-2(1H)-quinolinone derivative (2) that increases the expression of SMN2 by 2-fold with an EC

Indexed as

AnimalsCell LineCyclizationGene ExpressionHumansMiceMicrosomes, LiverMuscular Atrophy, SpinalQuinolonesRNA, MessengerSolubilityStructure-Activity RelationshipSurvival of Motor Neuron 2 ProteinQuinolonesRNA, MessengerSurvival of Motor Neuron 2 ProteinSpinal muscular atrophySurvival motor neuron

Identifiers

PMID29103974
PMCPMC5701662
OpenAlexW2765241324

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.